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Parathyroid carcinoma is a rare malignant endocrine tumor accounting for only 0.5% to 5% of all primary
hyperparathyroidism. Among these malignancies, only 10-25% are nonfunctioning. After the review of the
literature we could only ascertain a number of 25 cases reported worldwide, since 1929, our case being the
26th, but the first with a very aggressive pathology, treated with chemotherapy scheme usually used for
neuroendocrine tumors. Considering these facts, every single case presented is a step forward in defying the
clinical presentation, for the awareness of the clinicians, and also in establishing standard adjuvant therapies.
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Parathyroid carcinoma is one of the very rare malignant
endocrine tumors accounting for only 0.5% to 5% of all
primary hyperparathyroidism [1]. Among these malig-
nancies, only 10-25% are nonfunctioning [2], with
normal values of parathyroid hormone (PTH). The diffi-
culties in diagnosing these tumors rise not only because
of the absence of symptoms of hyperparathyroidism, but
also because of the hardship of the positive pathologic
diagnosis [1-4].
After the review of literature we could only ascertain a
number of 25 cases reported worldwide, since 1929
[5-31]. The present case is the 26th, being the first with
a very aggressive pathology, treated with chemotherapy
scheme usually used in the therapy of neuroendocrine
tumors.
We present the case of a 51-years-woman referred
for an indolent cervical mass measuring 2.5 cm in the
right supraclavicular area with slight evolution during
the last five years. Cervical ultrasound revealed a
hypoechogenic nodule located in the lower part of
the right thyroid lobe, without any other lesions
worth being mentioned. The serum hormones were* Correspondence: doina.piciu@gmail.com
1Department of Nuclear Medicine and Endocrine Tumours, Ion Chiricuţă
Institute of Oncology, 34-36, Republicii St, 400015, Cluj-Napoca, România
2Department of Oncology, Iuliu Hatieganu University of Medicine and
Pharmacy, Cluj-Napoca 400023, România
Full list of author information is available at the end of the article
© 2013 Piciu et al.; licensee BioMed Central Lt
Commons Attribution License (http://creativec
reproduction in any medium, provided the orfound in normal range, as follows: thyroid stimulating
hormone (TSH) was 1.21 mIU/L (N.V. 0.2-4.2 mIU/L);
free-thyroxin (FT4) was 14.4 pmol/L (N.V. 12–
22 pmol/L); calcium 9.1 mg/dL (N.V. 8.6-10.2 mg/
dL); PTH was 54 ng/L (N.V.15-65 ng/L) and the anti-
thyroid peroxidase antibodies (Anti-TPO) were nega-
tives. Chromogranin A (Cg A) was 38 μg/L (N.V.
27–94 μg/L) and 5-hydroxiindolacetic acid (5-HIAA)
was 4.2 mg/24 hours (N.V. 2–9 mg/24 hours). We
performed the fine needle aspiration biopsy (FNAB)
and a 2 ml volume of clear liquid was extracted, the
cytology showing only colloid and amorphous mater-
ial. Three years later, the patient was readmitted with
a recurrence of the mass, located in the same area.
The computed tomography scan (CT Scan) showed a
nodule of 1 cm located in the lower part of the right
thyroid lobe and another 2 cm tumor located near
the thyroid gland, adherent to it and with close con-
nection with the jugular vein (Figure 1). At this pre-
sentation, the serologic parameters were also in
normal ranges. It was decided the total thyroidec-
tomy, right selective lymphadenectomy and the ra-
dical resection of the tumor, of the jugular vein and
of a part of the adjacent muscle. On Hematoxylin
and Eosin (H&E) staining the tumor was composed
of clear, partially oxyphil cells, showing atypia and
nuclear pleomorphism with increased mitotic activity
(Figure 2). At the periphery of the tumor a remnant
of non-tumoral parathyroid tissue was still visible,d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Pre-operative computed tomography of non- functional
parathyroid carcinoma (arrowhead) displacing the trachea and
the jugular vein, in the right anterior cervical area.
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thyroid gland presented the microscopy of a nodular
goiter, without any signs of malignancy; all the lymph
nodes resected were disease free.
The tumor cells presented the following immuno-
histochemical (IHC) profile: cytokeratin AE1/AE3 in-
tensely positive; cytokeratin 7 antibody (CK7) focally
positive; neuron specific enolase (NSE) intensely
positive; Chromogranin A focally positive; gross cys-
tic disease fluid protein (GCDFP15) focally positive
in rare, isolated cells; progesterone receptor (PR)Figure 2 HE, 400×: Detail of nuclear atipia and multiple mitotic
figures, with an atypical one in the center of the image.weakly positive (1%); estrogen receptor (ER) negative;
cytokeratin 20 antibody (CK20) negative; Thyro-
globulin negative; Calcitonin negative; Synaptophisin
negative; Neural cell adhesion molecules (CD56)
negative; Mammaglobin negative; proliferating index
(Ki67) staining (Figure 3) showed a high proliferative
index (70%).
The histopathological diagnosis was probably of
right parathyroid carcinoma; the normal levels of
PTH and calcium enforced the PTH staining. Due to
the impossibility of performing the analysis in the
Institute, the accurate diagnosis was not set at that
time and the block was sent for a second opinion in
a national center, results showing that the PTH was
negative. The confusing results misled the clinicians
and made them unable to decide the treatment strat-
egy. The capsular invasion and the infiltration of the
adjacent muscle represented criteria for radiotherapy
as adjuvant therapy; but the primary diagnostic of
possible neuroendocrine tumor, with lack of response
to external beam radiation and the presence of vas-
cular emboli with high Ki-67 proliferation index
(70%) were arguments for the chemotherapy scheme.
The clinicians decided to start the chemotherapy cy-
cles as indicated for the neuroendocrine tumors:
Etoposide (Vepesid, VP16) 120 mg/sqm day 1–3 and
Carboplatin AUC 5 =450 mg/day (VP16 + Carbo). A
third histopathological report was demanded to the
experts in Athens, Greece. Their findings indicated
that PTH was extensively positive (Figure 4) and the
final diagnosis was of non-functional parathyroid
carcinoma. With this result, after 4 cycles of chemo-
therapy, the systemic treatment was discontinued.
The replacement thyroid hormone therapy with 100
micrograms Levo-thyroxine daily was started andFigure 3 Ki67, 100×: Ki67 immunostaining, demonstrating a
high proliferation index in the tumor.
Figure 4 PTH, 100×: Tumor showing positive PTH immunostaining.
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normal ranges. The follow-up was carried on every
3 months and consisted in determination of the TSH
and FT4, PTH, calcium and cervical CT Scan, chest
CT Scan and abdominal MRI. All the examinations
were constantly normal (Figure 5). The latest check-
up was performed at 15 months after surgery and
showed no relapse and the highly aggressive path-
ology did not express an aggressive clinical behavior.
In our study, the lack of reference on this pathology
leaded the clinicians to establish a chemotherapy proto-
col (VP16+ Carbo), used for the first time in the context
of this condition.Figure 5 Computed tomography of the neck region, one year
after therapy (surgery and chemotherapy); no local recurrence
or regional metastases.Non –functioning parathyroid carcinoma is an
exceptionally rare malignancy, therefore any expe-
rience must be known, in order to improve its diag-
nostic and therapy.
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